George Kumar, Senior Director at AstraZeneca, shared on LinkedIn:
“Fifty years ago, the discovery of monoclonal antibodies transformed biomedical science and health care.
This breakthrough not only paved the way for life-changing treatments but also stands as a powerful reminder of how open collaboration and the free exchange of ideas can drive innovation that changes lives.”
More posts featuring George Kumar on OncoDaily.